By Professor Deborah Cromer

Preprints

Stadler E; Khan SR; Elias KM; Egilmezer E; Phetsouphanh C; Hastak P; Hewavisenti RV; Joshi RV; Turner T; Cromer D; Sasson SC; Davenport MP; Khoury DS, 2026, Immunogenicity and vaccine effectiveness of COVID-19 vaccines in people on immunosuppressive therapies, http://dx.doi.org/10.64898/2026.09.16.26363194

Aggarwal A; Stella A; Walker G; Akerman A; Milogiannakis V; Brilot F; Amatayakul-Chantler S; Roth N; Coppola G; Schofield P; Jackson J; Lenthall H; Mazigi O; Langley D; Lu Y; Forster C; McAllery S; Mathivanan V; Fitcher C; Hoppe AC; Munier CML; Jack H-M; Cromer D; Darley D; Matthews G; Christ D; Khoury D; Davenport M; Rawlinson W; Kelleher A; Turville S, 2022, SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern, http://dx.doi.org/10.21203/rs.3.rs-1207364/v1

Cromer D; Steain M; Reynaldi A; Schlub TE; Wheatley AK; Juno JA; Kent SJ; Triccas JA; Khoury DS; Davenport MP, 2021, SARS-CoV-2 variants: levels of neutralisation required for protective immunity, http://dx.doi.org/10.1101/2021.08.11.21261876

Khoury DS; Cromer D; Reynaldi A; Schlub TE; Wheatley AK; Juno JA; Subbarao K; Kent SJ; Triccas JA; Davenport MP, 2021, What level of neutralising antibody protects from COVID-19?, http://dx.doi.org/10.1101/2021.03.09.21252641

Cao P; Klonis N; Zaloumis S; Khoury DS; Cromer D; Davenport MP; Tilley L; Simpson JA; McCaw JM, 2017, A mechanistic model quantifies artemisinin-induced parasite growth retardation in blood-stage Plasmodium falciparum infection, http://dx.doi.org/10.48550/arxiv.1701.05302

Khoury DS; Steain M; Triccas JA; Sigal A; Davenport MP; Cromer D, A meta-analysis of Early Results to predict Vaccine efficacy against Omicron, http://dx.doi.org/10.1101/2021.12.13.21267748

Stadler E; Cromer D; Ogunlade S; Ongoiba A; Doumbo S; Kayentao K; Traore B; Crompton PD; Portugal S; Davenport MP; Khoury DS, A role for super-spreaders in carrying malaria parasites across the months-long dry season, http://dx.doi.org/10.1101/2022.04.28.22274398

Khoury DS; Schlub TE; Cromer D; Steain M; Fong Y; Gilbert PB; Subbarao K; Triccas JA; Kent SJ; Davenport MP, Correlates of protection, thresholds of protection, and immunobridging in SARS-CoV-2 infection, http://dx.doi.org/10.1101/2022.06.05.22275943

Le TP; Conway E; Akpan E; Abell I; Abraham P; Baker CM; Campbell PT; Cromer D; Lydeamore MJ; McDonough Y; Mueller I; Ryan G; Walker C; Wang Y; Carvalho N; McVernon J, Cost-effective boosting allocations in the post-Omicron era of COVID-19 management, http://dx.doi.org/10.1101/2023.11.14.23298536

Lee WS; Selva KJ; Davis SK; Wines BD; Reynaldi A; Esterbauer R; Kelly HG; Haycroft ER; Tan H-X; Juno JA; Wheatley AK; Hogarth PM; Cromer D; Davenport MP; Chung AW; Kent SJ, Decay of Fc-dependent antibody functions after mild to moderate COVID-19, http://dx.doi.org/10.1101/2020.12.13.20248143

Stadler E; Chai KL; Schlub TE; Cromer D; Polizzotto MN; Kent SJ; Beecher C; White H; Turner T; Skoetz N; Estcourt L; McQuilten ZK; Wood EM; Khoury DS; Davenport MP, Determinants of passive antibody efficacy in SARS-CoV-2 infection, http://dx.doi.org/10.1101/2022.03.21.22272672

Docken SS; Macairan A; Schlub TE; Fennessey CM; Varco-Merth B; Picker LJ; Okoye AA; Immonen TT; Cromer D; Keele BF; Davenport MP, Dissecting the steps in early Simian Immunodeficiency Virus dissemination following mucosal and intravenous infection of rhesus macaques, http://dx.doi.org/10.1101/2025.03.24.644849

Lee WS; Tan H-X; Reynaldi A; Esterbauer R; Koutsakos M; Nguyen J; Amarasena T; Kent HE; Aggarwal A; Turville SG; Taiaroa G; Kinsella P; Liew KC; Tran T; Williamson DA; Cromer D; Davenport MP; Kent SJ; Juno JA; Khoury DS; Wheatley AK, Durable reprogramming of neutralising antibody responses following breakthrough Omicron infection, http://dx.doi.org/10.1101/2023.02.19.23286159

Koutsakos M; Lee WS; Reynaldi A; Tan H-X; Gare G; Kinsella P; Liew KC; Williamson DA; Kent HE; Stadler E; Cromer D; Khoury DS; Wheatley AK; Juno JA; Davenport MP; Kent SJ, Dynamics of immune recall following SARS-CoV-2 vaccination or breakthrough infection, http://dx.doi.org/10.1101/2021.12.23.21268285

Price DJ; Shearer FM; Meehan MT; McBryde E; Moss R; Golding N; Conway EJ; Dawson P; Cromer D; Wood J; Abbott S; McVernon J; McCaw JM, Early analysis of the Australian COVID-19 epidemic, http://dx.doi.org/10.1101/2020.04.25.20080127

Stadler E; Csolle M; Mitchell A; Egilmezer E; Elias KM; Bailey BA; Cromer D; Turner T; Khoury DS; Davenport MP, Evidence for cross-reactivity and protection against Bundibugyo virus disease after heterologous vaccination: a systematic review and meta-analysis, http://dx.doi.org/10.64898/2026.09.14.26362805

Wheatley AK; Juno JA; Wang JJ; Selva KJ; Reynaldi A; Tan H-X; Lee WS; Wragg KM; Kelly HG; Esterbauer R; Davis SK; Kent HE; Mordant FL; Schlub TE; Gordon DL; Khoury DS; Subbarao K; Cromer D; Gordon TP; Chung AW; Davenport MP; Kent SJ, Evolution of immunity to SARS-CoV-2, http://dx.doi.org/10.1101/2020.09.09.20191205

Selva KJ; Ramanathan P; Haycroft ER; Reynaldi A; Cromer D; Tan CW; Wang L-F; Wines BD; Hogarth PM; Downie LE; Davis SK; Purcell RA; Kent HE; Juno JA; Wheatley AK; Davenport MP; Kent SJ; Chung AW, Lasting first impression: Pre-existing immunity restricts mucosal antibody responses during Omicron breakthrough, http://dx.doi.org/10.1101/2023.03.28.23287848

Stadler E; Burgess MT; Schlub TE; Chai KL; McQuilten ZK; Wood EM; Polizzotto MN; Kent SJ; Cromer D; Davenport MP; Khoury DS, Monoclonal antibody levels and protection from COVID-19, http://dx.doi.org/10.1101/2022.11.22.22282199

Cromer D; Steain M; Reynaldi A; Schlub TE; Sasson SC; Kent SJ; Khoury DS; Davenport MP, Neutralising antibodies predict protection from severe COVID-19, http://dx.doi.org/10.1101/2022.06.09.22275942

Berry MT; MacIntyre CR; Cromer D; Hacker A; Davenport MP; Khoury DS, Optimal deployment of limited vaccine supplies to combat mpox, http://dx.doi.org/10.1101/2024.11.03.24316551

Conway E; Walker C; Lydeamore M; Golding N; Ryan G; Mavec D; Oates J; Kabashima G; Price DJ; Shearer F; Cromer D; Davenport MP; McCaw J; Eriksson EM; Hodgkin PD; Wu L; Le TP; Baker CM; Mueller I; McVernon J, Optimal timing of booster doses in a highly vaccinated population with minimal natural exposure to COVID-19, http://dx.doi.org/10.1101/2024.05.14.24307386

Cromer D; Reynaldi A; Hie A; Schlub TE; Juno JA; Wheatley AK; Kent SJ; Khoury DS; Davenport MP, Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates, http://dx.doi.org/10.1101/2024.02.08.24302032

Hao T; Ryan GE; Lydeamore MJ; Cromer D; Wood J; McVernon J; McCaw JM; Shearer FM; Golding N, Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19, http://dx.doi.org/10.1101/2024.10.17.24314397

Khoury DS; Docken SS; Subbarao K; Kent SJ; Davenport MP; Cromer D, Predicting the efficacy of variant-modified COVID-19 vaccine boosters, http://dx.doi.org/10.1101/2022.08.25.22279237

Hogan AB; Mitchell A; Stadler E; Chung Y; Reynaldi A; Elias KM; Docken S; Khoury DS; Schlub T; Davenport MP; Cromer D, Quantifying the association between neutralising antibodies and protection from RSV disease in infants and adults: A systematic review and meta-analysis, http://dx.doi.org/10.64898/2026.02.13.26346212

Cromer D; Reynaldi A; Steain M; Triccas JA; Davenport MP; Khoury DS, Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial, http://dx.doi.org/10.1101/2021.06.29.21259504

Stadler E; Cromer D; Mehra S; Adekunle AI; Flegg JA; Anstey NM; Watson JA; Chu CS; Mueller I; Robinson LJ; Schlub TE; Davenport MP; Khoury DS, Risk of Plasmodium vivax recurrences follows a 30-70 rule and indicates relapse heterogeneity in the population, http://dx.doi.org/10.1101/2022.05.18.22275180

Jin W; Mitchell A; Stadler E; Foster CSP; Schlub TE; Davenport MP; Cromer DP, Separating the effects of immune waning and viral evolution on COVID-19 vaccine effectiveness reveals improved effectiveness of updated vaccines, http://dx.doi.org/10.64898/2026.09.14.26363077

Elias KM; Khan SR; Stadler E; Schlub TE; Cromer D; Polizzotto MN; Kent SJ; Turner T; Davenport MP; Khoury DS, Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: A systematic review and meta-analysis, http://dx.doi.org/10.1101/2023.06.18.23291566

Back to profile page